


Galecto Biotech AB

Galectin inhibitors as new Cancer/Inflammation drug candidates



Galectin inhibitor, Td131_1, enhanced radio and chemosensitivity in Papillary Thyroid Cancer (same observed effect on Colon- and Kidneycancer).

Galectin inhibitor: Small molecule (500-1000 Da). Up to 3 orders in magnitude higher activity than reference inhibitors.

Development stage: Clinical research (in-vitro/vivo).

Unmet need: Drug effectiveness, low toxicity and mortality.

Existing treatment:

Traditionally cancer has been treated with surgery, chemotherapy, hormones and radiation therapy, alone or in combination. The drawback is that this treatment also kills normal, unaffected cells.

Suggested Treatment:

Intended as a combination treatment together with cytotoxins and/or radiology. The galectin inhibitors hinder the cancer cells from growing, while the cytotoxins and/or radiation kill the cancer cells.

Target group:

Inflammatory Cancer and autoimmune generated inflammation. More than 25 million people are affected by cancer, and an estimated 5 million die each year.

Market:

The current market for chemotherapies is estimated at US\$42 billion and is forecast to increase approximately 17% to US\$49 billion by 2012.

Patents filed: 4 Galectin inhibitors [22-01-2001, 21-05-2004, 21-05-2004, 28-04-2009], Galectin inhibitor synthesis [16-05-2008].

Strategy: Out-licensing, spin-out.

Contact:

Dr. Bert Junno, Lund University Technology Group, +46-707-772209, bert.junno@forskarpatent.com

Dr. Mikael Lindstam, Lund University Technology Group, +46-766-333699, mikael.lindstam@forskarpatent.com